Harpoon Therapeutics filed its IPO paperwork Thursday, joining the white-hot cancer immunotherapy space that has seen many other biotech companies go public in 2018.
Harpoon, which plans to trade on the Nasdaq under the ticker “HARP,” generated $3.7 million in revenue for the nine months ended Sept. 30, with a net loss of $17.6 million, according to its filing with the Securities and Exchange Commission. Although its revenues are up from the $708,000 it generated in all of 2017, its net loss…
